Lasers in Surgery and Medicine · 2021 · 17 citations · 36 references
MedicineOncologyRadiation OncologyBreast OncologyRadiation SafetyRadiobiologyBreast Cancer RadiotherapyBreast Radiation CareHypofractionated Breast RadiotherapyManagement Of Acute Radiation ReactionsRadiation TherapyWhole-breast IrradiationAcute Radiation InjuryControl Group DesignHypofractionated Whole-breast IrradiationMatched Control GroupPhotobiomodulationPost-mastectomy RadiotherapyRadiation Dermatitis ManagementSkin Sensitivity Reactions
OBJECTIVES: To evaluate the efficacy of photobiomodulation therapy in breast cancer patients post-lumpectomy undergoing hypofractionated whole-breast irradiation (HF-WBI) for the prevention and management of acute radiodermatitis (ARD). MATERIALS AND METHODS: A randomized, multicentric clinical trial (LABRA trial, NCT03924011) was set up at the Limburg Oncology Center, including the Jessa Hospital (Hasselt, BE) and Ziekenhuis Oost-Limburg (Genk, BE). A total of 71 breast cancer patients planned to undergo HF-WBI were randomized to one of the two study arms: the control group (n = 32) or the PBM group (n = 39). The PBM group received the standard institutional skincare combined with PBM (2×/week) during the complete radiotherapy (RT) course. Patients in the control group received the standard skincare combined with placebo treatment (2x/week). Patients' skin reactions were evaluated weekly during the RT treatment by using the modified version of the Radiation Therapy Oncology Group (RTOG) criteria. RESULTS: At week 3 of RT, one patient presented a grade 2 and one patient a grade 3 skin reaction in the control group, while in the PBM group, all patients still presented grade 1 ARD. At the final RT session 28% of the patients presenting grade 2-3 ARD, while in the PBM group 10% presented grade 2 and no grade 3 ARD. PBM reduced the incidence of severe ARD by 18%. However, the difference was not significant (p = 0.053). CONCLUSION: Based on the LABRA trial results, PBM seems not able to reduce the incidence of severe ARD in breast cancer patients undergoing HF-WBI. Research in a larger patient population is recommended.
36
Joanne Haviland, John R. Owen, John Dewar et al. · The Lancet Oncology · 2013 · 1.5K citations · Full text
Biphasic Dose Response in Low Level Light Therapy
Ying‐Ying Huang, Aaron Chen, James D. Carroll et al. · Dose-Response · 2009 · 1.1K citations · Full text